TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29961161
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg every 4 weeks (q4w)
Study: 29961161
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg every 4 weeks (q4w)
Study: 24699939
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg every 2 weeks (q2w)
Study: 21956255
Drug: Micafungin 50
Normalized name: micafungin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 50 mg/day
Study: 21956255
Drug: Micafungin 150
Normalized name: micafungin 150 MG in 150 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 150 mg/day
Study: 21956255
Drug: Micafungin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (all doses)
Study: 16241027
Drug: No antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiseptic agent
Study: 12914870
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg or carvedilol 25 mg twice daily after a 4-week dose titration period
Study: 10340366
Drug: Tremacamra (367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremacamra (367 microg per nostril per dose, total of 4.4 mg/d)
Study: 7546157
Drug: CyA‐NOF (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA‐NOF (7.5 mg/kg)
Study: 31709738
Drug: Gliclazide modified
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide modified release 120 mg
Study: 30193295
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (FEC followed by paclitaxel and trastuzumab)
Study: 30193295
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (Paclitaxel and trastuzumab followed by FEC and trastuzumab)
Study: 29240863
Drug: Efinaconazole 10%
Normalized name: EFINACONAZOLE 10% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 10% topical solution, once-daily for 48 weeks, with two 12-week post-treatment follow-ups (at week 60 and 72)
Study: 29240863
Drug: Efinaconazole 10%
Normalized name: EFINACONAZOLE 10% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 10% topical solution, once-daily for 48 weeks
Study: 15157254
Drug: Biotinylated RBCs
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotinylated RBCs plus unlabeled allogeneic RBCs (1.0 mL of biotinylated RBCs plus 15 mL per kg of unlabeled allogeneic RBCs)
Study: 2072515
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural administration of 1% mepivacaine at a rate of 2 ml.hr‐1
Study: 2072515
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus administration of 1% mepivacaine 4-5 times daily
Study: 2072515
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy including infusion of Ringer's solution and diuretics (Control group)
Study: 6653649
Drug: Penbutolol (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (i.v. doses of 3, 6, and 12 mg)
Study: 6653649
Drug: Penbutolol (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (i.v. doses)
Study: 6653649
Drug: Penbutolol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (oral doses of 40, 80, and 120 mg)
Study: 6653649
Drug: Penbutolol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (oral doses)
Study: 6653649
Drug: Penbutolol (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (i.v. administration)
Study: 6653649
Drug: Penbutolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (all doses)
Study: 28323806
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain management plus perioperative nonsteroidal anti-inflammatory drugs
Study: 22035157
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly (BIW)
Study: 17894653
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Study: 17894653
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Study: 14978550
Drug: Zinc chelate
Normalized name: glycine zinc chelate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc chelate 1 mg/kg daily for 3 months
Study: 11915705
Drug: Intraosseous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraosseous infusion technique
Study: 11915705
Drug: Traditional drugs
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drugs
Study: 8085688
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g orally every 6 hours)
Study: 8085688
Drug: Cimetidine (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (continuous intravenous, titrated to maintain gastric pH at 4.0)
Study: 19712155
Drug: Deltamethrin suspension
Normalized name: decamethrin
DrugBank: Deltamethrin (DB13600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin suspension concentrate (SC)
Study: 17043157
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (2 ng/kg per minute) during spironolactone (50 mg per day)
Study: 10675427
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm for 24 hours, then 5 ppm for 96 hours)
Study: 31563977
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Study: 31563977
Drug: Glossotonsillar sulcus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glossotonsillar sulcus infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Study: 30053199
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to a pre-defined algorithm in a tight control regimen
Study: 27513278
Drug: Sirolimus therapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus therapy for 2 years at doses adjusted to maintain a trough blood level of 5-15 ng/ml
Study: 26702788
Drug: Conventional Cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Cigarette (CC)
Study: 18803446
Drug: Memantine and
Normalized name: donepezil, memantine and Ginkgo folium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine and donepezil (individually or in combination)
Study: 12182748
Drug: ABT-229 5
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 5 mg b.d.
Study: 12182748
Drug: ABT-229 10
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 10 mg b.d.
Study: 12182748
Drug: ABT-229 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 2.5 mg b.d.
Study: 12182748
Drug: ABT-229 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 (all doses)
Study: 10350664
Drug: Cerivastatin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.05 to 0.3 mg/day)
Study: 10350664
Drug: Simvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (5 to 40 mg/day)
Study: 7703043
Drug: Doxorubicin (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (270 to 300 mg/m2 cumulative dose)
Study: 1838289
Drug: Control (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (similar treatment without magnesium)
Study: 30382824
Drug: RTX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX plus MMF (1000-1200 mg/m2/day, maximum 2 g/day, twice daily for 17 months)
Study: 20565725
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg oral salmon calcitonin (sCT)
Study: 20565725
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT)
Study: 17384931
Drug: Extended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended daily dialysis with filtration (EDDf)
Study: 14607735
Drug: TACE+MLT (melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE+MLT (melatonin 20 mg/d orally, 7 days before TACE)
Study: 7485886
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml isobaric 0.5% bupivacaine intrathecally without aspirating cerebrospinal fluid
Study: 7485886
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml isobaric 0.5% bupivacaine mixed with 1 ml cerebrospinal fluid (total 4 ml)
Study: 7485886
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml isobaric 0.5% bupivacaine mixed with 2 ml cerebrospinal fluid (total 5 ml)
Study: 2258790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 160 mg verapamil with 25 mg hydrochlorothiazide and 50 mg triameterene
Study: 7218018
Drug: 30 cc
Normalized name: TITANIUM DIOXIDE 2.5 mg in 100 mg / ZINC OXIDE 7.2 mg in 100 mg TOPICAL CREAM [Arbonne Intelligence Pollution Defense SPF30 CC Cream - Light Shade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 cc of milk of magnesia plus 5 cc of cascara
Study: 29425477
Drug: Sumac capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumac capsules (500 mg/twice daily)
Study: 22085227
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks
Study: 22085227
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy alone for 4 weeks
Study: 17593233
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period A)
Study: 17593233
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period B and C)
Study: 12519875
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of GH treatment (3 IU/m2 x d)
Study: 12519875
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of GH treatment (6 IU/m2 x d)
Study: 12519875
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of GH treatment (both dosage groups)
Study: 9169959
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg daily for 1 week, followed by 400 mg daily for 7 weeks
Study: 20710020
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg(‐1) bolus dose followed by a 5‐20‐40‐120 min, 10‐8‐6‐5 mg kg(‐1) h(‐1) infusion.
Study: 16171718
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone replacement (n = 9)
Study: 12767571
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 150 mg administered orally on days 5 through 9 of the CC-induced cycle
Study: 10489026
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 22 microg weekly
Study: 10489026
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 44 microg weekly
Study: 1881695
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + Metronidazole
Study: 26999243
Drug: sLPD (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: sLPD (0.6 g/kg/d with 0.09 g/kg/d keto acids)
Study: 26999243
Drug: NPD (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPD (1.0 g/kg/d)
Study: 24534120
Drug: CT-guided fiducial
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided fiducial seed placement with concurrent biopsy
Study: 22186223
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with potassium bromide (1 g, tid) and methimazole (10 mg, tid)
Study: 22186223
Drug: Methimazole only
Normalized name: Methimazole only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole only (10 mg, tid) with starch placebo (1 g, tid)
Study: 20397591
Drug: Suspicion as
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspicion as a receptor's personal disposition
Study: 12721780
Drug: Alcohol (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.25, 0.50, 0.75 g/kg based on total body water)
Study: 12721780
Drug: No alcohol
Normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alcohol administration
Study: 10226770
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) administered orally to 24 patients
Study: 10226770
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of 21 patients without pentoxifylline administration
Study: 8679274
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation with beta-carotene (30 mg/d) and alpha-tocopherol (400 IU/d)
Study: 6413133
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acid (BcAA) enriched parenteral nutrition at doses of 0.16, 0.3, 0.5, and 0.7 g/kg . day
Study: 6413133
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acid (BcAA) enriched parenteral nutrition
Study: 23907163
Drug: Curriculum progression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curriculum progression adjustments based on formative assessments (e.g. repeat lessons, skip lessons) every 4 weeks.
Study: 20600032
Drug: Budesonide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (3 mg, three times daily or twice daily) + Azathioprine (1-2 mg/kg/d)
Study: 20600032
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/d, tapered to 10 mg/d) + Azathioprine (1-2 mg/kg/d)
Study: 20600032
Drug: Budesonide (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (after 6 months of prednisone) + Azathioprine (1-2 mg/kg/d)
Study: 12626350
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine therapy
Study: 10741622
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral nisoldipine with 200 mL grapefruit juice (G0)
Study: 10741622
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral nisoldipine with 200 mL grapefruit juice (G14)
Study: 10741622
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral nisoldipine with water (control)
Study: 10741622
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral nisoldipine with water (G38)
Study: 10741622
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral nisoldipine with water (G72)
Study: 10741622
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral nisoldipine with water (G96)
Study: 9015467
Drug: Ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 100 mg once daily
Study: 7604800
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg once daily
Study: 6352622
Drug: ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime 2 g bd
Study: 6352622
Drug: cefamandole 2
Normalized name: cefamandole 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefamandole 2 g tds and tobramycin 80 mg bd
Study: 26164019
Drug: Calcitriol (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.025 μg) once daily for 14 days
Study: 26164019
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily for 14 days
Study: 23374729
Drug: 0.5% PRO2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% PRO2000 gel
Study: 20851460
Drug: 2% PRO2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% PRO2000 gel
Study: 15708255
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) radiotherapy, 2 Gy daily up to 60 Gy in 6 weeks
Study: 11870157
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (64.8 Gy)
Study: 11870157
Drug: Standard-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose radiation therapy (50.4 Gy)
Study: 299220
Drug: T‐antigen immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐antigen immunotherapy combined with cytostatic therapy
Study: 30607757
Drug: Culturally-adapted Cognitive
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally-adapted Cognitive Processing Therapy (CPT)
Study: 21421179
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg/d
Study: 21421179
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg/d
Study: 21421179
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 70 mg/d
Study: 21421179
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) (all doses combined)
Study: 15126920
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C (1g/day) and E (800 mg/day) for 8 consecutive days
Study: 7632128
Drug: GH substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH substitution treatment
Study: 332439
Drug: 26 mg
Normalized name: RNA 1.26 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 mg EACH
Study: 332439
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg EACH
Study: 332439
Drug: 33 mg
Normalized name: inulin 833 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 mg EACH
Study: 31125266
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with etoposide-cisplatin (EtoCis)
Study: 23207373
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral controlled‐release morphine
Study: 16621339
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus CM
Study: 16621339
Drug: Sertraline-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline-only
Study: 16621339
Drug: Sertraline conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline conditions
Study: 10475180
Drug: Dalteparin (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (subcutaneous, twice daily for 3 months)
Study: 8693440
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine sulphate 1 mg/ml (5 ml)
Study: 8693440
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (5 ml)
Study: 18689559
Drug: 700 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 IU/day of supplemental vitamin D(3) and 500 mg/day of supplemental calcium
Study: 15974900
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg; two 40 mg tablets once daily)
Study: 1761666
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment with human menopausal gonadotrophin (HMG)
Study: 29607625
Drug: Turmeric tonic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric tonic, administered twice a day for 9 weeks
Study: 29607625
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice a day for 9 weeks
Study: 25571684
Drug: Bifidobacterium bifidum
Normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium bifidum DN‐173 010 (1 x 10(10) cfu/g) in probiotic fruit yogurt, 110 g per day for 2 weeks
Study: 25571684
Drug: Placebo fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo fruit yogurt, 110 g per day for 2 weeks
Study: 16680620
Drug: Neurocognitive enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive enhancement therapy (NET) + paid work therapy (WT)
Study: 16680620
Drug: Paid work
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paid work therapy (WT)
Study: 11940541
Drug: Enoxaparin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1.0 mg/kg subcutaneously every 12 hours +/- initial 30 mg intravenous bolus)